Review of Restless Legs Syndrome

Save

JAMA has published a full read review of RLS - restless leg syndrome - a frequent, but often unrecognized, cause of poor sleep and the resultant hazards of insomnia.

Emergency Department Visits by Rheumatoid Patients

Save

Smartphones and Rheumatoid Flares

Save

Nurse Practitioner Independence

Save

A JAMA Viewpoint article reports on a March 2025 Nurse Practitioner (NP) Entrepreneurship Summit in Boston in March 2025 identifying barriers and opportunities to NP-owned medical practices.

The 2025 Rheumatology Year in Review

Save

The year 2025 presented numerous advances in rheumatology and related inflammatory and autoimmune disorders ranging from several new groundbreaking FDA approvals/indications, drug developments, game-changing guidelines and practices that will impact patient care for rheumatic diseases.

Advanced Practitioner Biologic Prescriptions for Psoriasis

Save

Advanced practice clinicians (APCs; nurse practitioners and physician assistants) deliver a large share of US dermatologic care, accounting for 37% of clinicians and 27% of dermatology visits by 2020. A current JAMA Dermatology reports APC drug spending trends in dermatology, with a focus on specialty medications (eg, biologics).

Spread of Psoriatic Disease from Skin to Joints

Save

Approximately 20 to 30 percent of all people who suffer from psoriasis also develop painful inflammation in their joints over time. If left untreated, psoriatic arthritis can lead to permanent damage to bones and joints.

Antirheumatic drug use with rheumatoid arthritis pregnancies

Save

A nationwide Norwegian registry study of rheumatoid arthritis (RA) pregnancies showed that while medication use increased during pregnancy, many discontinued treatment during pregnancy, only to resumed it after childbirth.

Nursing Shortage Could Worsen Due to Limited Student Loans

Save

In November, we reported on nursing groups that pushed back against a Trump administration proposal to de-list nursing as a professional degree for purposes of student borrowing. In this report, we look ahead to see what might happen as a result of the policy change.

Diffuse Alveolar Hemorrhage in Rheumatic Disease

Save

Subcutaneous Anifrolumab in SLE

Save

Manzi et al. have published the results of the TULIP-SC trial that showed that weekly subcutaneous (SC) anifrolumab, when given to severe SLE patients, had comparable efficacy and safety to the approved intravenous (IV) anifrolumab. 

2026 Resolutions (1.9.2026)

Save

Dr. Jack Cush reviews the news, announcements and journal articles from this past week on RheumNow.com. More on Variable bendability, a better way to treat RA, and a novel advance for GLP1a in PsA; and 2026 Resolutions!

GLP-1 Agonist plus IL-17 Inhibition in Obese Psoriatic Arthritis

Save

Lilly announced the topline results from its phase 3b "TOGETHER PsA" trial, showing that the combination use of ixekizumab (Taltz) and tirzepatide (Zepbound) was superior to IXE alone, yielding both significant weight loss and ACR50 disease control in adults with active psoriatic arthritis (PsA).

Subcutaneous Anifrolumab Effective in Lupus

Save

A new study published in Arthritis & Rheumatology demonstrates that subcutaneous administration of anifrolumab provides efficacy comparable to intravenous administration, offering a promising alternative for at-home care of patients living with moderate-to-severe systemic lupus erythematosus.

2025 Rheumatologists, In Memorium

Save

In 2025, Rheumatology lost many of our greatest clinicians, compatriots, and mentors. This is an honor roll for those who cared, taught, advised and supported many patients, and many of us.